Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 25, 2007

Cell Therapeutics Acquires Systems Medicine in a $20M Transaction

  • Cell Therapeutics (CTI) reports that it is buying Systems Medicine (SMi) in a stock-for-stock merger valued at $20 million. SMi stockholders could receive a maximum of $15 million in additional consideration, payable in either cash or shares of CTI common stock, upon the achievement of certain regulatory milestones.

    CTI notes that one of the main highlights of this transaction is that SMi’s Phase II anticancer candidate, Brostallicin, will fill its pipeline gap. While CTI’s  pixantrone and Xyotax are in late-stage development with launches expected in the first and second half of 2009, respectively, SMi’s drug has the potential to receive market approval by 2010.

    Brostallicin is a DNA minor groove binding agent. "Brostallicin has a potentially unique ability to become more active in tumors that are resistant to other cancer drugs," according to Jack W. Singer, M.D., CMO at CTI. "The extensive preclinical profiling of this agent, coupled with the fact that the EORTC (European Organization for Research and Treatment of Cancer) has advanced Brostallicin to a randomized Phase II trial in first-line treatment of sarcoma as a result of a successful Phase II effort in patients with prior therapy, underscores the potential of this product."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »